<DOC>
	<DOCNO>NCT00829465</DOCNO>
	<brief_summary>Liver cancer highly invasive malignancy rate surgical resection 28 % . After diagnosis , average survival rate patient le 50 % 6 month , le 24 % 1 year 5 % 5 year . The TACE treatment , theoretical basis blood supply Liver cancer , obviously well non-surgical therapy , term tumor regression , AFP decrease , survival time evaluation quality life . However , overall effect yet satisfactory . As result , concern research drug liver cancer improve overall efficacy treatment liver cancer real important clinical significance social value . Licartin ( Iodine-131-Labeled Metuximab ) injection antibody drug new target drug China intellectual property right . It specific high affinity HAb18G/CD147 , liver cell membrane antigen . Labeled 131I take liver tissue , own high-dose concentration release β particle liver cancer cell kill cancer cell . The Second Military Medical University , Eastern Hepatobiliary Surgery Hospital , plan use treatment Licartin combine TACE patient unresectable hepatocellular carcinoma evaluate difference tumor size , AFP change , TTP , overall survival rate different treatment group .</brief_summary>
	<brief_title>Clinical Research Licartin Combined With TACE Treatment Unresectable Hepatocellular Carcinoma</brief_title>
	<detailed_description>Liver cancer highly invasive malignancy rate surgical resection 28 % . The TACE treatment , theoretical basis blood supply Liver cancer , obviously well non-surgical therapy , term tumor regression , AFP decrease , survival time evaluation quality life . Licartin injection antibody drug new target drug China intellectual property right . It specific high affinity HAb18G/CD147 , liver cell membrane antigen . Labeled 131I take liver tissue , own high-dose concentration release β particle liver cancer cell kill cancer cell . The Second Military Medical University , Eastern Hepatobiliary Surgery Hospital , plan use treatment Licartin combine TACE patient unresectable hepatocellular carcinoma evaluate difference tumor size , AFP change , TTP , overall survival rate different treatment group .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1. participation entirely voluntary , good compliance , sign inform consent form person ; 2. diagnose hepatocellular carcinoma clinical method , image method tumor marker ; surgeon determine undergo surgery ; 3. confirm recurrent surgery pathology ; 4 . KPS score physical state ≥ 60 point ; 5. liver function ChildPugh A B class 1 . General situation poor liver function ChildPugh C class ; 2. serious heart , kidney blood system diseases patient ; 3. poor compliance ; 4. allergy history biological agent state allergy ; 5. pregnancy breastfeed woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>